The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy

Table 2

The demographic and clinical characteristics of the study group.

Group	De novo RRMS	INF	FG	NT	Control
N	24	32	39	26	41
Age (years)	43.05 ± 12.73	40.50 ± 9.45	36.49 ± 11.67	33.96 ± 8.45	39.46 ± 12.30
Gender (% of females)	66.67	71.88	56.41	76.92	78.05
Disease duration (years)	NA	4.39 ± 4.51	6.66 ± 4.27	5.96 ± 3.35	NA
EDSS (score)	2.52 ± 1.65	1.98 ± 0.86	3.08 ± 1.10	3.08 ± 1.14	NA
ARR (N)	0.84 ± 0.83	0.25 ± 0.44	0.37 ± 0.64	0.12 ± 0.33	NA
Gd + MRI lesions (N)	0.76 ± 0.83	0.43 ± 1.13	0.09 ± 0.39	0.12 ± 0.61	NA
T2 MRI lesions (N)	19.05 ± 3.99	18.53 ± 4.38	20.25 ± 1.86	18.50 ± 4.90	NA

De novo RRMS: patients with a newly diagnosed relapsing-remitting multiple sclerosis; RRMS INF: RRMS patients treated with interferon beta; FG: RRMS patients treated with fingolimod; NT: RRMS patients treated with natalizumab; EDSS: Expanded Disability Status Scale; ARR: annualized relapse rate; NA: nonapplicable.